Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story?

mesenchymal-epithelial transition (MET) non-small cell lung cancer (NSCLC) oncogene predictive biomarkers targeted therapy tyrosine kinase inhibitors (TKIs)

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
14 Jun 2023
Historique:
received: 20 05 2023
revised: 11 06 2023
accepted: 12 06 2023
medline: 29 6 2023
pubmed: 28 6 2023
entrez: 28 6 2023
Statut: epublish

Résumé

In recent years, we have seen the development and approval for clinical use of an increasing number of therapeutic agents against actionable oncogenic drivers in metastatic non-small cell lung cancer (NSCLC). Among them, selective inhibitors, including tyrosine kinase inhibitors (TKIs) and monoclonal antibodies targeting the mesenchymal-epithelial transition (MET) receptor, have been studied in patients with advanced NSCLC with

Identifiants

pubmed: 37373267
pii: ijms241210119
doi: 10.3390/ijms241210119
pmc: PMC10299133
pii:
doi:

Substances chimiques

Proto-Oncogene Proteins c-met EC 2.7.10.1
Protein Kinase Inhibitors 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

Cancer Biol Ther. 2019;20(9):1183-1186
pubmed: 31131689
N Engl J Med. 2014 Nov 20;371(21):1963-71
pubmed: 25264305
Cancer Cell. 2010 Jan 19;17(1):77-88
pubmed: 20129249
Oncotarget. 2021 Aug 31;12(18):1802-1810
pubmed: 34504652
Target Oncol. 2023 Jan;18(1):105-118
pubmed: 36459255
J Thorac Oncol. 2020 Jan;15(1):80-90
pubmed: 31622732
Ann Transl Med. 2015 Apr;3(6):83
pubmed: 25992382
Mol Cancer. 2022 Jan 26;21(1):31
pubmed: 35081970
Clin Cancer Res. 2013 Jun 1;19(11):2941-51
pubmed: 23553846
Mol Cancer Ther. 2011 Dec;10(12):2298-308
pubmed: 21926191
Lung Cancer (Auckl). 2021 May 20;12:35-50
pubmed: 34295201
J Thorac Oncol. 2019 Apr;14(4):737-741
pubmed: 30639620
Ann Oncol. 2019 Aug 1;30(8):1321-1328
pubmed: 31125062
Lung Cancer. 2020 Dec;150:21-25
pubmed: 33045465
Front Mol Biosci. 2018 Oct 24;5:86
pubmed: 30406111
Invest New Drugs. 2013 Aug;31(4):833-44
pubmed: 23275061
JTO Clin Res Rep. 2022 Jul 22;3(9):100381
pubmed: 36082279
Diagn Pathol. 2015 Jul 28;10:130
pubmed: 26215852
J Clin Oncol. 2016 Mar 10;34(8):794-802
pubmed: 26215952
J Thorac Oncol. 2015 May;10(5):e29-e31
pubmed: 25898962
J Thorac Oncol. 2020 May;15(5):741-751
pubmed: 32169477
J Biomed Sci. 2020 Jan 2;27(1):1
pubmed: 31894001
Proc Jpn Acad Ser B Phys Biol Sci. 2010;86(6):588-610
pubmed: 20551596
Curr Signal Transduct Ther. 2011;6(2):146-151
pubmed: 25197268
JCO Precis Oncol. 2023 Feb;7:e2200482
pubmed: 36848606
J Clin Oncol. 2017 Feb;35(4):412-420
pubmed: 27937096
Transl Lung Cancer Res. 2021 Jun;10(6):2667-2682
pubmed: 34295669
J Thorac Oncol. 2020 Apr;15(4):628-636
pubmed: 31945494
Lancet Respir Med. 2020 Nov;8(11):1132-1143
pubmed: 32479794
Ther Adv Med Oncol. 2011 Nov;3(1 Suppl):S7-S19
pubmed: 22128289
Mol Med. 2018 Sep 24;24(1):50
pubmed: 30249178
J Thorac Oncol. 2016 Aug;11(8):1293-1304
pubmed: 27262212
Biochim Biophys Acta. 2013 Jan;1833(1):122-39
pubmed: 23085373
Drugs. 2021 Sep;81(14):1665-1670
pubmed: 34455538
Nat Rev Cancer. 2018 Jun;18(6):341-358
pubmed: 29674709
Cancer Discov. 2020 Jul;10(7):922-934
pubmed: 32532746
Lancet Oncol. 2016 Dec;17(12):1661-1671
pubmed: 27825638
Front Oncol. 2022 Sep 23;12:1017026
pubmed: 36212500
Invest New Drugs. 2016 Jun;34(3):397-8
pubmed: 26892698
Nat Rev Cancer. 2012 Jan 24;12(2):89-103
pubmed: 22270953
Int J Mol Sci. 2022 Nov 11;23(22):
pubmed: 36430388
Front Oncol. 2022 Oct 21;12:1004198
pubmed: 36338701
Lung Cancer. 2022 Jan;163:59-68
pubmed: 34923203
ESMO Open. 2021 Dec;6(6):100319
pubmed: 34837746
N Engl J Med. 2020 Sep 3;383(10):931-943
pubmed: 32469185
N Engl J Med. 2020 Sep 3;383(10):944-957
pubmed: 32877583
Ann Oncol. 2018 Oct 1;29(10):2085-2091
pubmed: 30165371
J Clin Oncol. 2021 Oct 20;39(30):3391-3402
pubmed: 34339292
JTO Clin Res Rep. 2022 Sep 09;3(10):100407
pubmed: 36217329
J Clin Invest. 2022 Apr 15;132(8):
pubmed: 35426374
Nat Cancer. 2021 Apr;2(4):377-391
pubmed: 35122001
Clin Cancer Res. 2019 Feb 15;25(4):1248-1260
pubmed: 30352902
J Thorac Oncol. 2023 Apr;18(4):419-435
pubmed: 36441095
J Clin Oncol. 2022 Oct 1;40(28):3310-3322
pubmed: 35816666
Clin Cancer Res. 2013 Oct 15;19(20):5699-710
pubmed: 23989980
J Cancer. 2018 Apr 23;9(10):1836-1845
pubmed: 29805710
Lancet Respir Med. 2021 Oct;9(10):1154-1164
pubmed: 34166627
Nat Rev Clin Oncol. 2020 Sep;17(9):569-587
pubmed: 32514147
Lung Cancer. 2021 Nov;161:55-59
pubmed: 34536732
Nat Rev Mol Cell Biol. 2010 Dec;11(12):834-48
pubmed: 21102609
Cancers (Basel). 2022 May 14;14(10):
pubmed: 35626038
J Thorac Oncol. 2021 May;16(5):850-859
pubmed: 33545388
N Engl J Med. 2023 May 11;388(19):1767-1778
pubmed: 37163623
Transl Lung Cancer Res. 2021 Mar;10(3):1536-1556
pubmed: 33889528
Cancers (Basel). 2023 Jan 18;15(3):
pubmed: 36765572
Transl Lung Cancer Res. 2023 Feb 28;12(2):346-368
pubmed: 36895930
PLoS One. 2019 Oct 15;14(10):e0223926
pubmed: 31613934
Clin Cancer Res. 2019 May 15;25(10):3164-3175
pubmed: 30674502
Ann Oncol. 2018 Dec 1;29(12):2392-2393
pubmed: 30339198
Ann Oncol. 2023 Apr;34(4):339-357
pubmed: 36872130
JCO Precis Oncol. 2021 Aug 25;5:
pubmed: 34476332
Lung Cancer. 2023 Apr;178:254-268
pubmed: 36924573
Lung Cancer. 2023 Apr;178:66-74
pubmed: 36806896
Front Pharmacol. 2022 Mar 17;13:808855
pubmed: 35370682
Clin Lung Cancer. 2022 May;23(3):195-207
pubmed: 35272955
Clin Cancer Res. 2019 Dec 15;25(24):7312-7319
pubmed: 31416808
Ther Adv Med Oncol. 2022 Dec 26;14:17588359221144108
pubmed: 36601633
Oncotarget. 2017 Aug 4;8(40):68221-68229
pubmed: 28978110
Mol Oncol. 2014 Mar;8(2):378-88
pubmed: 24389243
Lung Cancer. 2017 Jan;103:27-37
pubmed: 28024693
Lung Cancer. 2015 Dec;90(3):369-74
pubmed: 26791794
Oncologist. 2019 Sep;24(9):e930-e942
pubmed: 30833489
Biochem Soc Trans. 2021 Apr 30;49(2):645-661
pubmed: 33860789
J Clin Pathol. 2015 Jun;68(6):405-9
pubmed: 25987653
Eur J Pharm Sci. 2019 Aug 1;136:104938
pubmed: 31132401
JCO Precis Oncol. 2023 Feb;7:e2200674
pubmed: 36848608
Cancer Discov. 2021 Nov;11(11):2726-2737
pubmed: 34099454
Genes Chromosomes Cancer. 2022 May;61(5):244-260
pubmed: 34997651
J Thorac Oncol. 2021 Apr;16(4):572-582
pubmed: 33309988
J Thorac Oncol. 2016 Sep;11(9):1493-502
pubmed: 27343443
Invest New Drugs. 2021 Apr;39(2):477-487
pubmed: 33052556
Clin Cancer Res. 2017 Nov 1;23(21):6661-6672
pubmed: 28765324
Cancer Res. 2014 Feb 1;74(3):884-95
pubmed: 24305878
N Engl J Med. 2013 Jun 20;368(25):2385-94
pubmed: 23724913
Ann Oncol. 2019 Dec 1;30(12):1985-1991
pubmed: 31584608
J Thorac Oncol. 2021 Jun;16(6):1017-1029
pubmed: 33676017
J Clin Oncol. 2022 Oct 1;40(28):3323-3343
pubmed: 35816668
Clin Lung Cancer. 2015 Sep;16(5):e101-4
pubmed: 25769807
J Thorac Oncol. 2015 May;10(5):e33-e34
pubmed: 25898965
Cancer Discov. 2015 Aug;5(8):850-9
pubmed: 25971938
Science. 2007 May 18;316(5827):1039-43
pubmed: 17463250
Nat Med. 2020 Jan;26(1):47-51
pubmed: 31932802
Clin Cancer Res. 2011 Nov 15;17(22):7127-38
pubmed: 21918175
Lung Cancer. 2021 Apr;154:142-145
pubmed: 33667719
Cancer Discov. 2015 Aug;5(8):842-9
pubmed: 25971939
JCO Precis Oncol. 2017;2017(1):
pubmed: 29527595
J Thorac Oncol. 2019 Oct;14(10):1753-1765
pubmed: 31279006
Trends Cancer. 2016 Jul;2(7):350-364
pubmed: 27819059
Lung Cancer. 2022 Jan;163:96-106
pubmed: 34942494
Oncotarget. 2018 Feb 08;9(17):13682-13693
pubmed: 29568386
Clin Cancer Res. 2020 Mar 15;26(6):1237-1246
pubmed: 31822497
J Thorac Oncol. 2019 Nov;14(11):2003-2008
pubmed: 31382039
Respir Res. 2023 Jan 25;24(1):28
pubmed: 36698189
J Clin Oncol. 2015 Aug 20;33(24):2667-74
pubmed: 26169611

Auteurs

Calogera Claudia Spagnolo (CC)

Medical Oncology Unit, Department of Human Pathology "G. Barresi", University of Messina, 98122 Messina, Italy.

Giuliana Ciappina (G)

Medical Oncology Unit, Department of Human Pathology "G. Barresi", University of Messina, 98122 Messina, Italy.

Elisa Giovannetti (E)

Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrje Universiteit, 1081HV Amsterdam, The Netherlands.
Cancer Pharmacology Lab, Fondazione Pisana per la Scienza, 56017 San Giuliano, Italy.

Andrea Squeri (A)

Medical Oncology Unit, Department of Human Pathology "G. Barresi", University of Messina, 98122 Messina, Italy.

Barbara Granata (B)

Medical Oncology Unit, Department of Human Pathology "G. Barresi", University of Messina, 98122 Messina, Italy.

Chiara Lazzari (C)

Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO)-IRCCS, 10060 Torino, Italy.

Giulia Pretelli (G)

Department of Surgery, Oncology and Gastroenterology, University of Padova, 35128 Padova, Italy.

Giulia Pasello (G)

Department of Surgery, Oncology and Gastroenterology, University of Padova, 35128 Padova, Italy.
Oncologia Medica 2, Istituto Oncologico Veneto, IRCCS, 35128 Padova, Italy.

Mariacarmela Santarpia (M)

Medical Oncology Unit, Department of Human Pathology "G. Barresi", University of Messina, 98122 Messina, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH